Better Health. Better Life.


Our Mission

M Pharmaceutical is focused on providing drug treatments and biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes.


Our Objective

M Pharmaceutical is committed to developing and commercializing its innovative drug treatments and biomedical technologies which offer the end user realistic solutions based on the principles of reduced invasiveness and enhanced effectiveness.

Our Drug Treatments

CHELATEXX is a novel formulation of Orlistat, patented until 2030 in the U.S.  Orlistat is FDA-approved for weight management and sold by Roche as Xenical® (prescription) and by GlaxoSmithKline as alli® (over-the-counter).  Proven safe and effective in over 100 clinical trials. Orlistat is the best-selling weight loss medication of all time with peak sales over $900 million in 2007. The CHELATEXX formulation addresses side effects associated with Orlistat, which have led to the decline in sales to approximately $200 million in recent years. 

CHELATEXX is intended to maintain the efficacy of Orlistat while minimizing its socially unacceptable side effects. Unlike other weight loss drugs:

  • Orlistat is not an amphetamine
  • Orlistat does not affect the central nervous system
  • Orlistat is not systemically absorbed
  • Orlistat is the only FDA-approved OTC weight loss drug because of its safety
  • Orlistat is the only FDA-approved weight loss drug for adolescent patients (age 12-18)


Our Biomedical Technologies


Board of Directors


Brain Keane, BSc, Interim President and CEO

  • 17 years in capital markets experience
  • Experience with investment funds
  • Experience working in several investment banks

Dr. Christopher Andrews, M.D., MSc, FRCPC, Director

  • Gastroenterologist, faculty member of the Department of Medicine at the University of Calgary and graduate of the Mayo Clinic in Rochester, MN
  • Specialist in stomach disorders and physiology, with advanced training in gastrointestinal motility and function
  • Masters Degree in Clinical Health Research from the Mayo Clinic

D. Richard Skeith, BA/JD, Director

  • BA (Hons) in Economics, University of Alberta; JD Faculty of Law, University of Alberta
  • Practicing Lawyer with specialized focus on publicly traded companies
  • Extensive experience as an Officer or Director of multiple public companies in sectors including pharmaceuticals, mining, oil and gas and real estate


Offices in Vancouver, BC and Calgary, AB

Head Office

Suite 430-580 Hornby (P) 604-428-0511
Vancouver, BC (F) 604-428-0512
V6C 3B6 (E) email

Investor Relations: 604-428-0511